Chifeng Wedge Pharmaceutical Co., Ltd is an integrated pharmaceutical company comprising of Research & Development, Pharmaceutical Raw Material Production, Solid and Liquid Finished Products Manufacturing and Domestic as well as Foreign Trade.

Our company has APIs, Tablets, Capsules, Granules, Ointments, Creams, Solutions, Liniments of eight formulations for a total of 85 varieties.

Company in 2004 through the first GMP certification and in 2009 through the re-certification. In order to ensure and improve the quality of our products, our company has rebuilt the plant and purchased a number of leading domestic production equipments and quality testing equipments.

Our company aims to be a pharmaceutical manufacturing enterprise with a certain research & development capabilities, strong quality assurance capacity and providing quality services to professional medical marketing companies. And that, a lot of APIs, intermediates and finished products had been directly or indirectly exported to Japan, South Korea, USA, Netherlands and some countries of South America and African.

Synthesis workshop located in the west side of our company is mainly engaged in the production of APIs and intermediate products.

Our synthesis workshop covering an area of 1375.76 square meters consists of general area, recovery area and clean area three parts.

Synthesis workshop was equipped with 60 sets of production equipments, including glass-lined reactors, stainless steel reactors, hydrogenation reactors, high-temperature distillation stills, double tapered vacuum drier, dust-free crushers, three-foot centrifuges, rectifying towers, water circulation vacuum pumps, etc. Synthesis workshop completely have the ability to ensure the high-efficient production of APIs and intermediates.

At present the product varieties of synthesis workshop including Tosufloxacin Tosylate(second-class new drug of Chinese National Standard, owning proprietary intellectual property rights), annual production capacity is 10t; 3-aminopyrrolidine dihydrochloride(owning proprietary intellectual property rights), annual production capacity is 20t; Acetyl salicylic acid Zinc(fourth-class new drug of Chinese National Standard), annual production capacity is 10t; XanthinolNicotinate, annual production capacity is 30t; Nitrendipine, annual production capacity is 20t; Trepibutone, annual production capacity is 20t; Cimetidine, annual production capacity is 10t; Alginic Sodium, annual production capacity is 20t. In addition, our synthesis workshop also independent research and develop some intermediates and their derivatives, such as 3-aminopyrrolidine, 1-benzyl-3-aminopyrrlidine, etc.

Among them, Xanthinol Nicotinate:

Molecular formula: C19H26N6O6

Molecular weight: 434.45

CAS No.:437-74-1

Packing: 20kg/trum

Characteristics: White or gray powder.

Usage: Ischemic cerebrovascular disease and Apoplexy sequela.